U.S. flag

An official website of the United States government

NM_000535.7(PMS2):c.240C>G (p.Phe80Leu) AND Lynch syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 28, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003997028.2

Allele description [Variation Report for NM_000535.7(PMS2):c.240C>G (p.Phe80Leu)]

NM_000535.7(PMS2):c.240C>G (p.Phe80Leu)

Gene:
PMS2:PMS1 homolog 2, mismatch repair system component [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
7p22.1
Genomic location:
Preferred name:
NM_000535.7(PMS2):c.240C>G (p.Phe80Leu)
HGVS:
  • NC_000007.14:g.6003982G>C
  • NG_008466.1:g.10125C>G
  • NM_000535.7:c.240C>GMANE SELECT
  • NM_001322003.2:c.-166C>G
  • NM_001322004.2:c.-166C>G
  • NM_001322005.2:c.-166C>G
  • NM_001322006.2:c.240C>G
  • NM_001322007.2:c.25C>G
  • NM_001322008.2:c.25C>G
  • NM_001322009.2:c.-166C>G
  • NM_001322010.2:c.-166C>G
  • NM_001322011.2:c.-645C>G
  • NM_001322012.2:c.-645C>G
  • NM_001322013.2:c.-166C>G
  • NM_001322014.2:c.240C>G
  • NM_001322015.2:c.-245C>G
  • NP_000526.2:p.Phe80Leu
  • NP_001308935.1:p.Phe80Leu
  • NP_001308936.1:p.Arg9Gly
  • NP_001308937.1:p.Arg9Gly
  • NP_001308943.1:p.Phe80Leu
  • LRG_161t1:c.240C>G
  • LRG_161:g.10125C>G
  • NC_000007.13:g.6043613G>C
  • NM_000535.5:c.240C>G
  • NM_000535.6:c.240C>G
  • NR_136154.1:n.327C>G
Protein change:
F80L
Links:
dbSNP: rs143162541
NCBI 1000 Genomes Browser:
rs143162541
Molecular consequence:
  • NM_001322003.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322004.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322005.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322009.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322010.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322011.2:c.-645C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322012.2:c.-645C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322013.2:c.-166C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322015.2:c.-245C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_000535.7:c.240C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322006.2:c.240C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322007.2:c.25C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322008.2:c.25C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322014.2:c.240C>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_136154.1:n.327C>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
Observations:
1

Condition(s)

Name:
Lynch syndrome
Identifiers:
MONDO: MONDO:0005835; MedGen: C4552100

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004842141All of Us Research Program, National Institutes of Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain Significance
(Jun 28, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided108544not providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From All of Us Research Program, National Institutes of Health, SCV004842141.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (1)

Description

This missense variant replaces phenylalanine with leucine at codon 80 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/250832 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown108544not providednot provided1not providednot providednot provided

Last Updated: Oct 8, 2024